IACH News Podcasts

Give the high rate of advances in the field of clinical hematology, the IACH News initiative enables experts in the field and key opinion leaders share the most up to date information in a timely manner, and in a format that is, focused, engaging and easy to access.

February 24th- Defining Cure in Multiple Myeloma: A Community Consensus Moment

CME Congresses .

February 24th- Defining Cure in Multiple Myeloma: A Community Consensus Moment

February 23rd- Prof. Roni Shouval- Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma

CME Congresses .

February 23rd- Prof. Roni Shouval- Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma

February 22nd- Beyond the webinar: Chronic GVHD in 2026: From Frustration to Structured Progress

CME Congresses .

February 22nd- Beyond the webinar: Chronic GVHD in 2026: From Frustration to Structured Progress

February 16th- Dr. Marie Robin- Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability

CME Congresses .

February 16th- Dr. Marie Robin- Transplantation in patients with lower-risk MDS: a prospective phase 2 trial based on donor availability

February 15th- CML in 2026: From Disease Control to Functional Cure

CME Congresses .

February 15th- CML in 2026: From Disease Control to Functional Cure

February 9th- Dr. Hira Mian- Redefining the Treatment Landscape of Multiple Myeloma – Key Messages from the 2026 ASCO–Ontario Health Living Guideline

CME Congresses .

February 9th- Dr. Hira Mian- Redefining the Treatment Landscape of Multiple Myeloma – Key Messages from the 2026 ASCO–Ontario Health Living Guideline

February 4th- A New Step Forward in Chronic GVHD Care

CME Congresses .

February 4th- A New Step Forward in Chronic GVHD Care

February 4th- (in French) Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies

CME Congresses .

February 4th- (in French) Mantle Cell Lymphoma in 2026: From Chemo-Immunotherapy to Precision, Chemo-Free Strategies

February 3rd- Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND)- a global, phase 3, randomised controlled trial

CME Congresses .

February 3rd- Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND)- a global, phase 3, randomised controlled trial

February 2nd- Redefining Immunotherapy in Relapsed/Refractory Follicular Lymphoma

CME Congresses .

February 2nd- Redefining Immunotherapy in Relapsed/Refractory Follicular Lymphoma